BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study.
Tanguy Y. Seiwert(Georgetown University), Ezra E.W. Cohen(Moores Cancer Center), H. de Mont-Serrat, Alice Blackman(Boehringer Ingelheim (United States)), Didier Cupissol(Institut de Recherche en Cancérologie de Montpellier), Paul M. Clément(Universitair Ziekenhuis Leuven), J. Del Campo, Holger Thurm(Pfizer (United States))
Cited by 39
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2020|1.1k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994